Avitar, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AVTI research report →
Price Chart
About the company
Avitar, Inc. , through its subsidiaries, designs, develops, manufactures, and markets diagnostic test products and proprietary hydrophilic polyurethane foam disposables for medical, diagnostics, dental, and consumer applications in the United States. It offers ORALscreen 4 and ORALscreen DRUGOMETER, the oral fluid-based onsite assay systems, for detecting drugs of abuse, such as opiates, including heroin, morphine, codeine, and synthetic opiates comprising oxycocone-oxycontin, percoset, and hydrocodone-vicodin; cocaine, such as crack; marijuana; and methamphetamines, including meth and ecstasy.
- CEO
- Cory H. Gelmon
- IPO
- 1994
- Employees
- 36
- HQ
- Canton, MA, US
Get TickerSpark's AI analysis on AVTI
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.38K
- P/E
- -0.00
- PEG
- 0.00
- P/S
- 0.00
- P/B
- -0.00
- EV/EBITDA
- -3.10
- Div Yield
- 0.00%
- Gross Margin
- 26.94%
- Op Margin
- 87.98%
- Net Margin
- -72.75%
- ROE
- 25.07%
- ROIC
- -203.85%
Latest fiscal year · YoY change
- Revenue
- $3.11M-36.9%
- Gross Profit
- $836.70K-41.1%
- Op Income
- $2.73M
- Net Income
- $-2,259,629+39.0%
- EPS
- $-0.11+85.5%
- OCF Growth
- +33.9%
- FCF Growth
- +36.4%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -7.52
- RSI (14)
- 52
- Avg Volume
- 359
No earnings-call transcripts are available for AVTI yet.
- Free Float
- 100.0%
- Shares Outstanding
- 138.19M
- Float Shares
- 138.13M
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 28, 07 | PHILDIUS PETER P | sell | 27,905 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our AVTI coverage
Recent articles, reports, and earnings notes.
No research on AVTI yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate AVTI report →Head to Head Contrast: Avitar (OTCMKTS:AVTI) and Becton, Dickinson and Company (NYSE:BDX)
defenseworld.net · Dec 30
Critical Survey: Becton, Dickinson and Company (NYSE:BDX) and Avitar (OTCMKTS:AVTI)
defenseworld.net · Dec 1
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.